Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized placebo-controlled study of inebilizumab in adults with myasthenia gravis
MOH_2021-07-29_010171Phase 3Completed
- Sponsor
- Viela Bio
- Start
- Jun 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of inebilizumab in myasthenia gravis (MG) (3 arms), sponsored by Viela Bio. Started Jun 2021; status: completed.
02
Drugs
inebilizumab
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on MOH_2021-07-29_010171.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-07-29_010171.